
Talenom Plc: Disclosure under chapter 9, section 10 of the securities market act (Danske Bank A/S)
Talenom Plc, Stock exchange release 9 January 2023 at 17:45 EET
Talenom Plc: Disclosure under chapter 9, section 10 of the securities market act (Danske Bank A/S)
Talenom Plc has received an announcement from Danske Bank A/S on 9 January 2023. According to the announcement, the total number of Talenom shares owned by Danske Bank A/S increased above 5% of Talenom Plc’s total number of shares as a result of share transactions concluded on 6 January 2023.
Total position of Danske Bank A/S according to the notification:
% of shares and voting rights | % of shares and voting rights through financial instruments | Total of both in % | Total number of shares and voting rights of issuer | |
Resulting situation on the date on which threshold was crossed or reached | 5.07% | 5.07% | 44,923,197 | |
Position of previous notification (if applicable) | 4.99% | 4.99% |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
Number of shares and voting rights | % of shares and voting rights | |||
Class/type of shares ISIN code | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) |
FI4000153580 | 2,277,089 | 5.07% | ||
SUBTOTAL | 2,277,089 | 5.07% |
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
Danske Invest Select | 0.01% | 0.01% | |
Finnish Fund | 5.06% | 5.06% |
Further information:
Otto-Pekka Huhtala
CEO, Talenom Plc
+358 40 703 8554
otto-pekka.huhtala@talenom.fi
Talenom is an agile and progressive accounting firm established in 1972. Our business idea is to make daily life easier for entrepreneurs with the easiest-to-use digital tools on the market and highly automated services. In addition to comprehensive accounting services, we support our customers’ business with a wide range of expert services, as well as financing, account and payment traffic services. Our vision is to provide superior accounting, account and payment traffic services for SMEs.
Talenom’s growth history is strong – average annual net sales growth was approximately 16.2% between 2005 and 2021. In 2021, Talenom had on average 1,012 employees in Finland, Sweden and Spain at a total of 52 locations. Talenom’s share is quoted on the Main Market of Nasdaq Helsinki. Read more: sijoittajat.talenom.fi/en/
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Placeringsf. Nykredit Invest (Kapitalforening) – estimerede udlodninger for 20238.12.2023 15:37:01 CET | pressemeddelelse
På baggrund af de skattepligtige indtægter for 2023 har Placeringsf. Nykredit Invest (Kapitalforening) nu estimeret følgende ureviderede udlodninger for foreningens afdelinger for 2023: AfdelingISINValutaUdbytte pr. andelDanske FokusaktierDK0060231777DKK12,90Kredit Fokus KLDK0061066842DKK0,00 Det bemærkes, at der alene er tale om estimerede udlodninger, hvorfor der vil kunne ske ændringer. Der gøres endvidere opmærksom på at fx handelsaktivitet mv. i den resterende del af året kan påvirke de estimerede udlodninger i såvel opadgående som nedadgående retning. Endelige estimerede udlodninger vil blive offentliggjort på Nasdaq Copenhagen A/S den 24. januar 2024 og forventes udbetalt til investorerne den 2. februar 2024. Eventuel henvendelse vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted, tlf. 44 55 92 00. Med venlig hilsen Placeringsforeningen Nykredit Invest Tage Fabrin-Brasted, direktør Vedhæftet fil FB_Plac_NI_estimerede_udlodninger_8_12_2023
Storaktionærmeddelelse8.12.2023 15:25:58 CET | pressemeddelelse
Se vedhæftede Vedhæftet fil Selskabsmeddelelse 32_2023 Storaktionærmeddelelse_NCI
Investeringsforeningen Investin – estimerede udlodninger for 20238.12.2023 15:23:20 CET | pressemeddelelse
På baggrund af de skattepligtige indtægter for 2023 har Investeringsforeningen Investin nu estimeret følgende ureviderede udlodninger for foreningens afdelinger for 2023: AfdelingISINValutaUdbytte pr. andelEMD Local CurrencyDK0060542504DKK0,00Sampension Globale Aktier KLDK0061074861DKK3,10Sampension Obligationer KLDK0061076213DKK0,00I&T Nordiske Aktier Large CapDK0061276656DKK0,00I&T Globale Aktier ESG SelectDK0061276573DKK5,80 Det bemærkes, at der alene er tale om estimerede udlodninger, hvorfor der vil kunne ske ændringer. Der gøres endvidere opmærksom på at fx handelsaktivitet mv. i den resterende del af året kan påvirke de estimerede udlodninger i såvel opadgående som nedadgående retning. Endelige estimerede udlodninger vil blive offentliggjort på Nasdaq Copenhagen A/S den 16. januar 2024 og forventes udbetalt til investorerne den 25. januar 2024. Eventuel henvendelse vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted, tlf. 44 55 92 00. Med venlig hilsen Invest
Storaktionærmeddelelse8.12.2023 15:20:16 CET | pressemeddelelse
Se vedhæftede Vedhæftet fil Selskabsmeddelelse 31_2023 Storaktionærmeddelelse_MHI
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions8.12.2023 15:15:00 CET | Press release
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefitand stability in secondary endpoints including overall survival (OS)1,2 iDFS benefit remains consistent across key patient subgroups; among patients with stage II and stage III tumors, Kisqali lowered risk by 30% and 24.5%, respectively1,2 Latest analysis continues to show a well-tolerated safety profile in line with previously reported results, and quality of life for Kisqali patients preserved vs. endocrine therapy (ET) alone1,2,3 Risk of recurrence remains a short and long term concern; one in eight women treated with ET alone in NATALEE likely to experience invasive disease at 3 years1,2 Kisqali is currently approved in the metastatic setting, where it has consistently demonstrated statistically significant OS benefit across three Phase III trials4-15;Novartis has filed NATALEE results with EMA and will subm